STK-012 Monotherapy and in Combination Therapy in Patients with Solid Tumors

Active:	Yes
Cancer Type:	Head and Neck Cancer Kidney Cancer Lung Cancer Melanoma Ovarian Cancer Solid Tumor Unknown Primary	NCT ID:	NCT05098132
Trial Phases:	Phase I	Protocol IDs:	STK-012-101 (primary) NCI-2022-00633
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Synthekine
NCI Full Details:	http://clinicaltrials.gov/show/NCT05098132

Summary

This is a first-in-human, phase 1a/1b, multicenter, open-label, dose escalation study of
STK-012 as monotherapy and in combination therapy in patients with selected advanced
solid tumors.

Objectives

The phase 1a portion of the study is a dose escalation design to evaluate STK-012 as
monotherapy and in combination therapy in patients with selected solid tumors. The phase
1b portion of the study includes dose expansions to evaluate STK-012 as monotherapy and
in combination therapy at the candidate recommended phase 2 dose (RP2D) in selected solid
tumor types.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.